Search

Workshop at the European Medicines Agency in Amsterdam, with online participation, on Friday 30 October 2026, 09:00 to 18:00 Amsterdam time (CET). It brings together regulators, policymakers, scientists, healthcare professionals, developers

Armata Pharmaceuticals announced on September 14, 2026 that the US FDA has granted Breakthrough Therapy designation to AP-SA02, its intravenous multi-phage product candidate for adjunct treatment of complicated Staphylococcus aureus bactere

Armata Pharmaceuticals announced on January 13, 2026 an FDA End-of-Phase 2 written response confirming that safety and efficacy data from its Phase 2a diSArm study support advancing AP-SA02, an intravenous S. aureus bacteriophage cocktail,

The European Medicines Agency's draft guideline on quality aspects of phage therapy medicinal products (EMA/CHMP/BWP/1/2024) clarifies the regulatory expectations for quality documentation of bacteriophage active substances and finished pro

Australia's Therapeutic Goods Administration consulted on a proposed time-limited GMP exemption for manufacturers of personalised bacteriophage therapy products, which are currently supplied as unapproved goods under the Special Access Sche

Cytophage Technologies announced on August 25, 2025 that it received two Letters of No Objection from Health Canada's Food Directorate for its OvaPhage egg-surface and PhageFend food-surface bacteriophage products. According to the company,

In a Form 8-K dated August 19, 2025, BiomX reported that the FDA placed a clinical hold on its Phase 2b study of BX004 in cystic fibrosis while it reviews data on a third-party nebulizer used to deliver BX004. The FDA raised no concerns abo

On 4 June 2025 the UK Medicines and Healthcare products Regulatory Agency (MHRA) published the UK's first official guidance to support the safe development and use of phage therapies, covering both combined phage products for common infecti

On 15 November 2024 the board of Portugal's medicines authority INFARMED approved, in Deliberação n.º 112/CD/2024, a guidance note on compounded medicines for phage therapy in hospitals: magistral preparations of bacteriophages made in a ho

PhageEurope (Phage EU) is a new coalition of likeminded stakeholders who represent phages in industry, the scientific community and civil society who wants to realize the full potential of phages in Europe. They are holding a webinar 11 Jul

The WHO's 4th Clinical Antibacterial Pipeline Advisory Group Meeting took place this week. Haileyesus Getahun, MD (Joint Secretariat on AMR at WHO) stated via Twitter that for the first time, available data on phage therapy was set to be ev

An international team of scientists are calling for the European Union to enforce non-animal antibody production, and phage display may be the ideal replacement. Report | Press release.

One of Intralytix's phage products, EcoShield (which targets E. coli O157:H7), has been approved by the FDA to be used more broadly. Now it can be used on ground beef (plus other meat cuts and on carcasses). Previously, it could only be use

One of Intralytix's phage products, EcoShield (which targets E. coli O157:H7), has been approved by the FDA to be used more broadly. Now it can be used on ground beef (plus other meat cuts and on carcasses). Previously, it could only be use

STOA workshop at the European Parliament in Brussels on 30 September 2026 on advancing phage therapy as an evidence-based strategy against antimicrobial resistance, with attention to regulatory, clinical and practical hurdles and to multidr

The House of Commons Science, Innovation and Technology Committee ran an inquiry into the antimicrobial potential of bacteriophages, prompted by a pitch to its My Science inquiry and asking how UK and EU regulation, which has largely limite

Arrowsmith (Tsukuba, Japan) completed a Series A round totaling ¥1.05 billion, with JAFCO, JIC-VGI and ANRI in the first close and DBJ Capital in the second, and held a pre-IND meeting with the US FDA on ARW001, its phage cocktail for Pseud

The official abstract book for the 9th World Conference on Targeting Phage Therapy includes over 48 contributions from 24 countries. Topics include phage therapy, One Health, and production, regulation and market access. Targeting Phage The

A second ASM Health Phage Therapy Coordination Network working group focuses on regulatory pathways and implementation resources for patient access. People with relevant experience were invited to apply. Dev Mittar — original commentary

The House of Commons Science, Innovation and Technology Committee's report The antimicrobial potential of bacteriophages follows an inquiry that received over 40 pieces of written evidence and held three oral evidence sessions. Among its re